Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing

• DOI: 10.1073/pnas.1617467114
• Publication Date: 2017-06-14T00:45:16Z
• Authors: Teng Fei; Yiwen Chen; Tengfei Xiao; Wei Li; Laura Cato; Peng Zhang; Maura B. Cotter; Michaela Bowden; Rosina T. Lis; Shuang G. Zhao; Qiu Wu; Felix Y. Feng; Massimo Loda; Housheng Hansen He; X. Shirley Liu; Myles Brown
• Keywords: Male; 0303 health sciences; RNA Splicing; Prostatic Neoplasms; Neoplasm Proteins; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; Ribonucleoproteins; Cell Line, Tumor; Humans; RNA, Neoplasm; CRISPR-Cas Systems; Genome-Wide Association Study

Significance Alternative RNA splicing and the spliceosome machinery have been implicated in cancer progression. A genome-wide CRISPR screen identified the RNA processing factor heterogeneous nuclear ribonucleoprotein L (HNRNPL) as required for prostate cancer growth by regulating alternative RNA splicing and circular RNA formation. HNRNPL and its RNA clients are overexpressed during prostate cancer progression, supporting their potential role as therapeutic targets.